Caresyntax GmbH

Based in Germany, Caresyntax GmbH offers a comprehensive surgical intelligence platform that enhances surgical workflows through data analytics, improving patient care and operational decision-making in healthcare settings. Caresyntax GmbH, founded in 2013, is headquartered in Berlin, Germany. The company specializes in surgical intelligence solutions that aid in optimizing surgical operations. The current CEO, Dennis Kogan, along with co-founders Bjoern von Siemens and Oksana Sventakh, has led the company through various phases, including its recent Series C funding round.

As of August 15, 2024, Caresyntax raised USD 80. 00 mn in Series C funding, following a total of 10 funding deals since its inception. This round involved participation from numerous investors such as BlackRock and Aescuvest, contributing to a total amount raised of USD 80. 00 mn.

Caresyntax provides a vendor-neutral surgical intelligence platform designed to streamline surgical workflows and enhance patient care through comprehensive data analytics. Their core product utilizes advanced AI technologies to capture and analyze data from various hospital systems, devices, and processes, creating actionable insights that optimize surgical performance and outcomes. The platform is used extensively by hospitals, surgical centers, and medtech partners to improve operational efficiency. Key users include surgeons, perioperative leaders, and surgical patients, with services tailored to clients particularly in North America, Europe, and Australia.

Caresyntax generates revenue primarily through B2B partnerships with healthcare institutions and medtech companies via subscription-based access to their surgical intelligence platform. Clients benefit from ongoing support and analytics services, which often include customized data solutions tailored to specific client needs. The platform's offerings are designed to provide substantial returns on investment, enhancing surgical quality and efficiency for clients in the healthcare sector. In 2022, Caresyntax recorded an EBITDA of USD -14,280,497.

80. In August 2024, Caresyntax secured USD 80. 00 mn in Series C funding to accelerate AI development and support customer adoption in the U. S.

and EMEA regions. The company plans to expand its product offerings, focusing on upcoming features that enhance data analytics capabilities, although specific launch dates have not been disclosed. Additionally, Caresyntax aims to penetrate new markets across Europe and Australia, leveraging the latest funding to enhance AI-driven insights and expand its customer base in healthcare.